Guy's Hospital, London SE1 9RT, United Kingdom.
Int J Surg. 2013;11(9):749-52. doi: 10.1016/j.ijsu.2013.08.018. Epub 2013 Sep 5.
The management of transitional cell carcinoma of the bladder (TCCB) presents a challenge to urological surgeons due to the diversity of patient factors, stage at presentation and propensity for disease recurrence and progression. Advances in the last decade have seen an evolution in techniques for diagnosis, treatment and ongoing surveillance. A good understanding of our patients, the disease and the available diagnostic and therapeutic options is essential for the management of this condition. We review the current literature focusing on the merits of recent advances in this field. Given the breadth of the subject, we have deliberately selected only the most relevant and recent advances already in clinical use.
膀胱移行细胞癌(TCCB)的管理对泌尿外科医生来说是一个挑战,因为患者的因素、就诊时的阶段以及疾病复发和进展的倾向存在多样性。在过去十年中,诊断、治疗和持续监测的技术有了进步。为了管理这种疾病,对我们的患者、疾病以及现有的诊断和治疗选择有一个很好的了解是至关重要的。我们回顾了当前的文献,重点介绍了该领域最近进展的优点。鉴于主题的广泛,我们只选择了已经在临床应用中最相关和最新的进展。